Facebook  Twitter  LinkedIn
+31 50 313 1905


dHOPE study

dHOPE study

19 may 2017

The group of Prof. Porte from the University Medical Center Groningen (UMCG, The Netherlands) has published about their results of the dHOPE DCD trial (Dual vessel liver perfusion with the Hypothermic Oxygenated Perfusion protocol). Ten transplants have been compared against twenty historical transplants. Read more about the trial below and in the full publication, available on Pubmed (https://www.ncbi.nlm.nih.gov/pubmed/28394402). This study has been published in the British Journal of Surgery.


Experimental studies have suggested that end-ischaemic dual hypothermic oxygenated machine perfusion (DHOPE) may restore hepatocellular energy status and reduce reperfusion injury in donation after circulatory death (DCD) liver grafts. The aim of this prospective case-control study was to assess the safety and feasibility of DHOPE in DCD liver transplantation.


In consecutive DCD liver transplantations, liver grafts were treated with end-ischaemic DHOPE. Outcome was compared with that in a control group of DCD liver transplantations without DHOPE, matched for donor age, donor warm ischaemia time, and recipient Model for End-stage Liver Disease (MELD) score. All patients were followed for 1 year.


liver assistTen transplantations involving liver grafts treated with DHOPE were compared with 20 control procedures. There were no technical problems. All 6-month and 1-year graft and patient survival rates were 100 per cent in the DHOPE group. Six-month graft survival and 1-year graft and patient survival rates in the control group were 80, 67 and 85 per cent respectively. During DHOPE, median (i.q.r.) hepatic adenosine 5'-triphosphate (ATP) content increased 11-fold, from 6 (3-10) to 66 (42-87) µmol per g protein (P = 0·005). All DHOPE-preserved livers showed excellent early function. At 1 week after transplantation peak serum alanine aminotransferase (ALT) and bilirubin levels were twofold lower in the DHOPE group than in the control group (ALT: median 966 versus 1858 units/l respectively, P = 0·006; bilirubin: median 1·0 (i.q.r. 0·7-1·4) versus 2·6 (0·9-5·1) mg/dl, P = 0·044). None of the ten DHOPE-preserved livers required retransplantation for non-anastomotic biliary stricture, compared with five of 20 in the control group (P = 0·140).


This clinical study of end-ischaemic DHOPE in DCD liver transplantation suggests that the technique restores hepatic ATP, reduces reperfusion injury, and is safe and feasible. RCTs with larger numbers of patients are warranted to assess the efficacy in reducing post-transplant biliary complications.


Our devices are all CE marked


News and publications  
   Donor Assist
   Kidney Assist-transport 
   Lung Assist  
   Liver Assist  
   Kidney Assist  
             Our technology  
            Bornholmstraat 84
9723 AZ Groningen
The Netherlands
+31 50 313 1905

Facebook Twitter LinkedIn

CE certificateafbeeldingiag
ISO 13485 certificateCOPE websiteafbeelding

Improve your organ procurement, test the organs and increase the amount of transplantable organs.
We offer the tools for optimal pre-conditoning, preservation and re-conditioning.
Organ Assist has the solution for you.
header imgfotofotofotofotofoto